Get sick from one strain, recover, and you can catch another.
For fifteen years, researchers at Brazil's Butantan Institute have pursued a single-dose answer to one of the tropics' most persistent threats. Now, as dengue claims lives and overwhelms health systems across Brazil in early 2024, that answer stands at the threshold of regulatory approval — a moment when science, urgency, and institutional capacity converge in ways that rarely align so clearly. The institute plans to submit its application to ANVISA by July, offering not only a tetravalent vaccine with strong efficacy data, but the manufacturing scale to deliver it to a nation that can no longer afford to wait.
- Brazil entered 2024 already in crisis — nearly 250,000 probable dengue cases and dozens of deaths in the first weeks alone, with the disease's four-strain biology making every recovered patient a candidate for a deadlier second infection.
- The Butantan Institute's candidate vaccine, fifteen years in development, has cleared Phase 3 trials with 79.6% overall efficacy and a safety record that saw fewer than 0.3% of volunteers experience serious side effects — all of whom fully recovered.
- Its defining advantage over the already-approved Qdenga is stark: one dose versus two, covering all four dengue serotypes simultaneously, a simplicity that could dramatically ease mass vaccination campaigns in resource-stretched settings.
- ANVISA has already engaged with the institute's preliminary data and signaled ongoing dialogue, with Butantan targeting a full regulatory submission between June and July 2024.
- The dengue push is not happening in isolation — Butantan has simultaneously filed for approval of a chikungunya vaccine showing 98.8% antibody response, as both mosquito-borne diseases surge through the same communities via the same vector.
- The question sharpening around both candidates is no longer scientific but logistical and temporal: whether regulatory approval will arrive before the next wave of transmission deepens the toll.
For fifteen years, researchers at Brazil's Butantan Institute have been working toward a single-dose dengue vaccine. By July 2024, if the final data holds, the institute plans to submit a full application to ANVISA — Brazil's health regulator — asking for authorization to manufacture and distribute the shot nationwide.
The urgency behind that timeline is not abstract. In the opening weeks of 2024, Brazil recorded nearly a quarter million probable dengue cases, with 24 confirmed deaths and 163 more still under investigation. The disease is particularly dangerous because of its biology: four distinct viral strains circulate simultaneously, and a second infection with a different strain dramatically raises the risk of severe illness and death.
The Butantan vaccine addresses this directly. It is tetravalent — targeting all four strains in a single attenuated-virus injection. Phase 3 trials involving more than sixteen thousand participants showed 79.6% overall efficacy, rising to 89.2% among those previously infected. Serious adverse events were rare, affecting fewer than 0.3% of volunteers, all of whom recovered fully.
What distinguishes the Butantan candidate from its main competitor, Takeda's Qdenga, is simplicity: one dose instead of two. That difference carries real weight in large-scale public health campaigns, particularly across a country as vast and logistically complex as Brazil.
Butantan is well-positioned to act on any approval. As Latin America's largest vaccine and serum producer, it already supplies the entirety of Brazil's national flu vaccination campaign and manufactures critical serums for venomous bites, bacterial toxins, and rabies. Scale, in other words, is not the obstacle.
Regulatory momentum is already building. ANVISA has reviewed preliminary trial data and indicated it will continue evaluating the institute's findings as they accumulate. Meanwhile, Butantan has also filed for approval of a chikungunya vaccine — developed with Franco-Austrian firm Valneva — that produced antibody responses in 98.8% of adolescent trial participants and was already approved by the U.S. FDA in November 2023.
Together, these two candidates represent something larger than individual approvals: the possibility that Brazil may finally have the tools to interrupt transmission of two diseases long treated as chronic, manageable burdens. Whether those tools arrive before the next surge is the question now pressing hardest on the calendar.
For fifteen years, researchers at Brazil's Butantan Institute have been chasing a single-dose dengue vaccine. In June, the last volunteer in their clinical trial will complete five years of monitoring. By July, if all goes as planned, the institute will submit its application to Brazil's health regulator, ANVISA, asking for permission to manufacture and distribute the shot.
The timing matters. In the first weeks of 2024 alone, Brazil recorded nearly a quarter million probable dengue cases. Twenty-four people had died, with another 163 deaths still under investigation. The disease has become a grinding public health crisis, and it's getting worse because dengue doesn't work like most infections. There are four distinct strains of the virus circulating. Get sick from one, recover, and you can catch another. When that second infection happens, the illness can turn severe—what doctors call dengue grave—and the risk of death climbs sharply.
The Butantan vaccine is tetravalent, meaning it targets all four strains at once. The virus in the shot is weakened, just strong enough to teach the immune system to recognize and fight the real thing, but not strong enough to cause actual illness. In Phase 3 trials involving more than sixteen thousand people, the vaccine showed 79.6 percent overall effectiveness. Among people who had already had dengue before, it worked 89.2 percent of the time. Even in those with no prior exposure, it hit 73.5 percent. Serious side effects were rare—fewer than three tenths of one percent of volunteers experienced them, and all recovered completely.
What sets the Butantan candidate apart from its main competitor, Qdenga from Japan's Takeda, is simplicity. Qdenga requires two doses. The Brazilian vaccine needs only one. That single injection contains all four virus types in attenuated form, grown in cells from African green monkeys using a technique the scientific community has studied and refined for decades. The virus is then purified, freeze-dried into powder, and packaged with a separate diluent that gets mixed in just before administration.
Butantan is not a small player in this space. It is Latin America's largest vaccine and serum producer and supplies the majority of Brazil's immunobiologicals. The institute manufactures every dose of flu vaccine used in the country's national vaccination campaign. It produces the serums that protect Brazilians from venomous animal bites, bacterial toxins, and rabies. If Butantan's dengue vaccine wins approval, the institute will have the capacity to manufacture it at scale.
The regulatory path is already in motion. ANVISA has met with Butantan researchers and reviewed preliminary data from the ongoing Phase 3 study. The agency has signaled that as clinical data accumulates, it will continue discussions with the institute. Approval, the agency said, depends on whether the final results prove the vaccine is both safe and effective. The institute is confident enough in its data that it has set a target: submit the full application between June and July.
While the dengue vaccine moves toward the finish line, Butantan has already taken another step forward. In December, the institute submitted a request to ANVISA for final approval of a chikungunya vaccine it developed with the Franco-Austrian pharmaceutical company Valneva. That vaccine was already approved in the United States by the FDA in November. In Brazilian Phase 3 trials with adolescents, it triggered antibody production in 98.8 percent of volunteers. Chikungunya, like dengue, is spread by the same mosquito—Aedes aegypti—and in early 2024, Brazil had recorded nearly fifteen thousand probable cases with three confirmed deaths.
The convergence of these two vaccine candidates points toward a shift in Brazil's disease landscape. For years, dengue was treated as a chronic problem, managed but not solved. Now, with a single-dose option potentially months away from approval, and with a chikungunya vaccine already in the regulatory queue, the country may finally have tools to interrupt transmission. The question is no longer whether vaccines exist. It is whether they will arrive in time.
Citações Notáveis
The weakened viruses trigger antibody production without causing disease and with minimal adverse reactions— Butantan Institute
Phase 3 is an essential stage to scientifically define the safety and efficacy profile of the vaccine— ANVISA
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is a single dose instead of two?
In public health, simplicity is power. One shot means fewer appointments, fewer missed doses, fewer people who start a series and never finish. In a country managing a quarter million dengue cases a year, that difference compounds.
The efficacy numbers—79.6 percent overall—is that good enough?
It's solid. You're not looking for perfection with vaccines. You're looking for enough protection to break transmission chains. Seventy-nine percent means most vaccinated people won't get sick, and those who do will likely have milder disease. That's enough to matter at scale.
Why did it take fifteen years to get here?
Dengue is complicated. Four strains, not one. You have to make sure the vaccine protects against all four without one strain overwhelming the others in the immune response. And you have to prove it's safe in tens of thousands of people across different ages. That takes time.
What happens if ANVISA says no?
Unlikely, but if it happened, the vaccine wouldn't reach Brazilian patients. Butantan could still sell it elsewhere—other countries have dengue—but the domestic crisis would persist. The institute has already done the hard work. Regulators just need to confirm it.
Is there a race here with Takeda's vaccine?
Not really a race. Qdenga is already approved in some countries. But in Brazil, Butantan's single dose is a genuine advantage. If both are available, doctors and patients will have a choice. Competition usually means better access.
What about the chikungunya vaccine they mentioned?
That's the next chapter. It's already approved in the U.S., and Butantan submitted for Brazilian approval in December. If both dengue and chikungunya vaccines get cleared, the institute becomes the source for protection against the two biggest mosquito-borne threats in the region.